Pricing Pressure Pays Off As Drug Spending Moderates Despite New Launches

A New IQVIA Institute report shows that rebates, discounts and limits on access to medicines are having the effect that payers want: drug spending growth is slowing and will soon plateau, even as new, high-cost brands come to market. PhRMA's view? Competitive markets keep costs down.

PharmacyReceipt-Dollars-PillBottles_1200x675

A new IQVIA Institute for Human Data Science report shows that significant rebates, discounts and limited access to medicines are keeping drug spending growth in check, though Pharmaceutical Research and Manufacturers of America (PhRMA) credits competition for slowing the compound annual growth rate (CAGR) for drug spending globally.

Clearly, both payer pressures on pricing and the need to price medicines competitively – especially in drug classes with multiple...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

29 Jul 2025

• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.